Indaptus Therapeutics, Inc. entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC on August 28, 2026. This agreement supersedes the prior June 1, 2022 arrangement and authorizes the company to sell up to $100,000,000 in shares of common stock through an at-the-market program. The filing includes a prospectus supplement dated August 31, 2026, linked to an effective Form S-3 shelf registration statement. Wainwright acts as sales agent for a 3.0% placement fee, with no obligation for the company to sell shares or for the agent to purchase them on a principal basis. Indaptus Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic diseases.
